Clinic Directory — coming soon. Are you an Australian peptide clinic?Apply to be listed →
Independent · Australian · Education only — not medical adviceAboutEditorial standardsHow we review
HomeEncyclopediaMazdutide

Mazdutide

GLP-1 / glucagon dual agonist (investigational)

Investigational

What it is

An investigational dual GLP-1/glucagon receptor agonist studied for weight management.

What the evidence shows

Early trial interest; long-term efficacy and safety data are still being gathered.

Safety & reported risks

Unregulated outside trials; gastrointestinal effects are reported in studies.

Status in Australia

Investigational — not approved or marketed as a medicine in Australia.

How it’s lawfully accessed

No lawful consumer supply. Access is only via an approved clinical trial.

Related peptides

RetatrutideTriple-agonist (investigational)InvestigationalSurvodutideGLP-1 / glucagon dual agonist (investigational)InvestigationalCagrilintideAmylin analogue (investigational)Investigational

Sources & further reading

This entry is general information about Mazdutide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.

Written by The Peptides.au editorial team
Editorial review Checked against current TGA, ARTG and AHPRA public guidance
Last updated 1 June 2026

This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.